Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bioequivalence requirements for generic products

R L Nation1, L N Sansom

  • 1School of Pharmacy and Medical Sciences, University of South Australia, Adelaide.

Pharmacology & Therapeutics
|April 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiomics informed mathematical model for meropenem and tobramycin against hypermutable Pseudomonas aeruginosa.

International journal of antimicrobial agents·2025
Same author

In pursuit of the triple crown: mechanism-based pharmacodynamic modelling for the optimization of three-drug combinations against KPC-producing Klebsiella pneumoniae.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same author

Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same author

Assessment and modelling of antibacterial combination regimens.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2017
Same author

Impact of vanB vancomycin-resistant enterococcal bacteraemia analysed as a time-varying covariate on length of hospital stay.

Epidemiology and infection·2014
Same author

Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2013

Generic pharmaceutical products require bioequivalence studies to ensure therapeutic equivalence to innovator products. This review examines global bioequivalence requirements, identifying areas for international harmonization.

Area of Science:

  • Pharmaceutical Sciences
  • Regulatory Science
  • Pharmacokinetics

Background:

  • Generic drugs must prove therapeutic equivalence to innovator products.
  • Bioequivalence, assessed via pharmacokinetic measurements, is key to demonstrating therapeutic equivalence.
  • Regulatory agencies worldwide have established procedures for generic drug approval.

Purpose of the Study:

  • To review bioequivalence requirements for generic pharmaceutical products.
  • To identify and highlight differences in these requirements among various countries.
  • To promote international harmonization of generic drug regulations.

Main Methods:

  • Review of existing regulatory guidelines and scientific literature on bioequivalence.
  • Comparative analysis of bioequivalence standards across different countries.

Related Experiment Videos

  • Identification of commonalities and discrepancies in regulatory approaches.

    • Main Results:

    • Bioequivalence is the primary basis for demonstrating therapeutic equivalence globally.
    • Pharmacokinetic data are commonly used to assess bioequivalence.
    • Significant variations exist in specific bioequivalence criteria and study designs among countries.

    Conclusions:

    • Harmonizing bioequivalence requirements can facilitate global generic drug access.
    • Addressing international differences in bioequivalence standards is crucial for regulatory efficiency.
    • Further collaboration is needed to align global regulatory approaches for generic medicines.